trials were successful. Features that were present among all of the successfully recruiting protocols were: (1) studies designed to recruit patients with regional or advanced-stage disease (2 of 2 protocols); and (2) studies that involved some investigational systemic therapy (3 of 3 protocols). Discussion. AA and HA cancer patients can be successfully accrued onto randomized clinical trials, but study design affects recruitment patterns. Increased socioeconomic disadvantages observed within minority-ethnicity communities results in barriers to screening and more advanced cancer stage distribution. Improving cancer early detection is critical in the effort to eliminate outcome disparities but existing differences in disease burden results in diminished eligibility for early-stage cancer clinical trials among minority-ethnicity patients.
The clinical trials mechanism is one of the most powerful strategies available for improving the standard of care and survival rates for cancer patients. Participation in a clinical trial requires much trust, compliance, and motivation at the patient level. At the provider level, it places substantial demands on time, staffing, and financial resources of the clinical practice. However, the fundamental elements of clinical trial design-standardized delivery of care and follow-up for novel treatments compared to preexisting approaches-are essential in the effort to make meaningful advances in cancer outcomes.
Findings from an oncology clinical trial cannot be reliably generalized unless the demographic profiles of the study participants and the larger, overall patient population are comparable. Unfortunately, minority racial/ethnic groups have historically been underrepresented in cancer clinical trials. Explanations for this accrual disparity include lack of trust in the health care system; socioeconomic disadvantages (because poverty rates are higher among racial/ethnic minorities and they are therefore less likely to receive cancer care in affluent facilities where clinical trials are offered); and lack of awareness of clinical trial benefits. Regardless of the explanation, disproportionately low accrual of racial/ethnic minorities raises questions regarding efficacy of the studied treatment across all racial/ethnic and socioeconomic strata.
The American College of Surgeons Oncology Group (ACOSOG) has previously published studies of our accrual patterns related to racial/ethnic identity, and with regard to potential accrual targets that account for racial/ethnic distribution of the general cancer population after accounting for particular organ site as well as stage at diagnosis. Table 1 summarizes the results of our studies with regard to developing accrual targets for African American and Hispanic/Latino Americans onto breast and thoracic clinical trials, based on data from general population demographics and the National Cancer Data Base. Here, we describe the racial/ethnic profiles of patients accrued onto the clinical trials of ACOSOG. We compare the features of the trials that were most successful in achieving accrual diversity with those that were the least successful.
METHODS
ACOSOG is a surgically based clinical trials cooperative group funded by the National Cancer Institute of the National Institutes of Health. We looked at the demographics of participants accrued to 10 completed and/or closed ACOSOG studies; we focused on distribution of African American (AA) and Hispanic/Latino American (HA) participants compared to white/European American participants because the largest magnitude disparities in cancer burden have reported for these population subsets. Racial/ethnic identity was assigned according to patientreported information ascertained at the time of protocol registration. All of the ACOSOG clinical trials were reviewed and approved by the institutional review boards of the participating cancer-treating facilities.
The 10 trials included in this report were selected if they had reached an accrual target of at least 100 participants and were either closed or nearly closed to further accrual. These 10 studies were conducted by the following ACO-SOG committees: Breast (three trials), Sarcoma (two trials), and Thoracic (five trials).
The clinical trials included in this evaluation were categorized by the following protocol features, which were AA African American, HA Hispanic/Latino American selected because of an a priori concern that these features might be correlated with ability to successfully recruit minority racial/ethnic groups for participation: (1) randomized versus nonrandomized study; (2) protocol designed for early-stage disease versus regional and/or locally advanced disease; and (3) protocol design featured an investigational drug/systemic therapy in conjunction with surgery versus protocol primarily studying a surgery/ surgical staging question. Accrual rates for the various evaluated ACOSOG protocols were then categorized as being ''successful,'' ''modestly successful,'' or ''unsuccessful'' with regard to proportions of participants self-identifying as being AA or HA (Table 2 ). Ranges for these categories were selected as a function of both general population demographics and estimates of the distribution of racial/ethnic minorities within specific cancer type, stratified by stage, and as previously reported as suggested accrual targets for breast and thoracic cancer by ACOSOG. 2 These accrual targets were presented to and promoted among the ACOSOG membership during plenary session lectures at ACOSOG annual meetings, at committee conference calls, and at both disease site committee and administrative committee meetings. Accrual targets for sarcoma and esophageal cancers were not previously developed by ACOSOG, and successful accrual diversity for these cancers was defined in correlation with general population demographics.
We then assessed frequency of successful recruitment diversity among protocols characterized by the various protocol features. The overall small sample sizes of evaluated studies and study features precluded statistical significance testing.
RESULTS
The 10 evaluated studies (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) ) are listed in Table 3 , representing breast, thoracic, and sarcoma cancer protocols. As shown in Table 4 , four studies (40%) were randomized clinical trials; eight (80%) were restricted to participants with early-stage/resectable disease; and three protocols (30%) included the study of some investigational systemic therapy approach.
As shown in Table 5 , eight trials (80%) were successful or modestly successful with regard to recruitment of AA and/or HA participants; only one trial (Breast Z1031) was successful in recruiting both AA and HA participants, and two trials were unsuccessful with regard to recruiting both AA and HA participants. Table 6 summarizes frequency of success/modest success among protocols with particular features. Threequarters of the randomized trial protocols were successful or modestly successful in recruiting AA and/or HA participants. Protocol features that were consistently associated with successful recruitment diversity were: (1) studies limited to recruitment of patients with regional or advanced-stage disease (2 of 2 protocols); and (2) studies that involved some investigational systemic therapy approach (3 of 3 protocols).
DISCUSSION
The National Institutes of Health (NIH) Revitalization Act of 1993 mandates that NIH-funded investigators accrue women and minorities onto clinical trials in numbers that are adequate for analyses. 3 Furthermore, many prominent cancer support and funding organizations such as the system. This fear of clinical research is pervasive, and it has been documented among potential clinical trial participants of all racial/ethnic backgrounds for both cancer and noncancer clinical trials, but it is particularly pronounced among racial/ethnic minorities. [4] [5] [6] [7] [8] [9] [10] [11] [12] Improving successful accrual diversity will require education and behavior modification at both the physician-provider and patient levels. Patients must be educated regarding the safety and advantages of clinical trial participation: enrollment onto a clinical trial can serve as a safeguard to ensure delivery of well-monitored and standardized care that is free of physician/provider bias and discriminatory practices. Physicians must be educated regarding the critical importance of diversity in the implementation of a meaningful clinical trial. The physician must also resist the temptation to assume that patients will not be interested in a clinical trial because of their ethnic background and/or socioeconomic status. Balanced presentation of all treatment options (including clinical trial participation) is crucial to the ethical practice of oncology. 13, 14 The findings that we summarize here confirm that eligible AA and HA patients commit to clinical trial participation in robust numbers when given the opportunity.
Cultural competence must be apparent throughout the various stages of protocol design, initiation, and interpretation of results. 15 Unfortunately, several investigators are reporting deficiencies in these areas. Adams-Campbell et al. demonstrated inherent barriers in clinical trial design that precluded AA from being eligible to participate in clinical trials in a Howard University study. 16 Simon et al. reported that AA breast cancer patients were far less likely to be offered a clinical trial compared to their white American counterparts. 17 Both investigators found that AA had relatively high rates of trial participation if they were eligible and if the trial was offered.
Governmental support for health care outreach programs will hopefully strengthen relationships between oncology providers and racial/ethnic minority populations. On June 29, 2005, President Bush signed into law the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005 (P.L. 109-18). The concept of patient navigators was first introduced by Dr. Harold P. Freeman as a strategy for improving delivery of comprehensive cancer screening, diagnostic, and treatment services. Use of navigators has been shown to improve breast cancer outcomes by strengthening mammography utilization and yielding earlier detection of disease; these trained patient assistance programs can also be utilized to improve recruitment and retention of diverse patient populations onto clinical trials. 18, 19 Many regulatory practices are now federally mandated as a direct consequence of past misbehaviors by clinical trialists. Noncompliance with these regulations may result in punitive action, such as monetary fines and forced closure of research programs. Ability to continue offering clinical trial participation therefore requires substantial time and staff resources, leaving only the most affluent health care facilities with the infrastructure to maintain regulatory compliance. Poverty is clearly associated with diminished effectiveness of basic cancer screening and early detection programs, and it is intuitively clear that financial support for clinical trial implementation is less likely to be available in public/safety net institutions. 20, 21 Because AA and HA are overrepresented among the impoverished and the underinsured, they are therefore also less likely to have access to private/university/academic centers where clinical trials are more commonly offered. This is an especially tragic result, because the contemporary clinical trials mechanism actually represents the safest strategy for racial/ethnic minority patients to receive standardized and appropriately monitored care. The clinical trial setting also provides more expedient opportunities to receive novel cancer treatments that might be otherwise unavailable either because of prohibitive costs or limited availability. Primary surgical study (n = 7) 5/7 (71%) 2/7 (29%)
AA African American, HA Hispanic/Latino American a For ''successful'' or ''modestly successful'' accrual of AA and/or HA (n = 8) vs. ''unsuccessful'' for accrual of both AA and HA (n = 3) with regard to accrual diversity ACOSOG has previously suggested that cancer clinical trials should consider using accrual targets for racial/ethnic minorities to improve the generalizability of study findings. ACOSOG has furthermore suggested that these targets should be defined by distribution of racial/ethnic minorities by cancer type and cancer stage because of well-documented variations in cancer burden. Our current analyses of ACOSOG accrual patterns suggest that there is ample room for improving the diversity of cancer clinical trial participants, but we have also shown that these clinical trial targets are indeed achievable. The 10 ACOSOG trials meeting the selection criteria of having at least 100 participants and being closed or nearly closed represented approximately half of all ACOSOG protocols activated during the development of this report. Although the total number of trials evaluated is relatively small, the patterns for accrual success are nonetheless relevant and promising with regard to future clinical trial recruitment efforts.
ACOSOG accrual sites are widely distributed throughout the United States. Specific details regarding accrual patterns for all ACOSOG trials by race/ethnicity, type of practice, and characteristics of ACOSOG investigator are unavailable at this time for this particular article; however, these features have been previously analyzed and reported by Leitch et al. in a study of the ACOSOG Z0010 Breast Sentinel Lymph Node trial. 22 Leitch et al. reported that nearly half of participating surgeons represented academic programs; nearly one-third represented community practices; and 75% of minority patients were accrued by onequarter of participating surgeons.
Accrual patterns from the ACOSOG protocols suggest that minorities may well be seeking out otherwiseunavailable treatments through the clinical trials process because the study of Gleevec for gastrointestinal stromal tumors had the most impressive accrual diversity. Gleevec did not receive U.S. Food and Drug Administration approval for this heretofore highly fatal cancer until after the trial results were released.
Trials for early stage cancers (especially operable thoracic tumors) were less likely to be successful in accruing AA and HA patients. This suggests that failure of cancer screening and early detection efforts among racial/ethnic minority communities may be yielding an inherently smaller pool of racial/ethnic minorities that are eligible to participate in clinical trials designed for early-stage disease. This was readily apparent in the ACOSOG Breast trials. The Z0010 trial had the earliest stage disease eligibility, requiring patients to have small, lumpectomyeligible tumors and clinically node-negative disease; this trial accrued less than 10% AA and HA participants. In contrast, the ACOSOG breast cancer trials for node-positive and/or locally advanced disease (Z0011 and Z0031) included larger proportions of AA and HA patients. Efforts to improve cancer surveillance and earlier detection are obviously essential for improved outcome (above all) as well as improved and more representative clinical trial eligibility. These observations also suggest that the development of additional clinical trials for women with later stage cancer could expand clinical trial opportunities for racial/ethnic populations that tend to present with more advanced disease.
The disparity in estimates for proportion of HAs in the general U.S. population compared with the proportion of HAs with a cancer diagnosis is noteworthy, and it correlates with the notably lower proportion of HAs accrued onto clinical trials. For example, Surveillance, Epidemiology, and End Results Program data as well as data from the National Cancer Data Base indicate that HAs account for less than 5% of the cancer population. The HA community is one of the most rapidly growing subsets of the American population, accounting for more than 13% of the current population and projected to account for 24% by the year 2050. 23 This disproportionately low frequency of HAs among the cancer patient population may be a reflection of differences in self-reported racial/ethnic identity related to demographics ascertained by the U.S. Census versus data obtained by cancer registries and clinical trialists. 24, 25 These differences made it more difficult to select accrual targets that are both achievable and representative of the cancer population as well as the general population. We suggested accrual targets of at least 5% for HAs onto most cancer clinical trials. Although this target is greater than the average 2-3% accrued onto past trials, investigators should consider the likelihood that HAs will comprise a much larger proportion of the future cancer patient population as the HA population expands and as ascertainment of racial/ethnic identity by cancer registries becomes more robust.
ACOSOG recognizes the widespread difficulties associated with recruitment of diverse patient populations onto their clinical trials. This cooperative group has worked aggressively to address and overcome barriers to accrual diversity through several strategies. The Education Committee develops patient-oriented printed materials regarding ACOSOG protocols, and these materials are reviewed by the Special Populations and Patient Advocates committees. Unfortunately, these materials are not routinely available in non-English languages. The Patient Advocates and Special Populations committees also work together closely by meeting at the ACOSOG Annual Meetings, and by implementing a luncheon speaker series designed to inform the ACOSOG membership regarding disparities in oncology. This speaker series emphasizes the importance of using the clinical trial mechanism to improve our understanding of cancer risk and outcome disparities and has included topics such as geriatric oncology, the cancer burden of HA communities, disparities in thoracic oncology, and use of genotyping/ancestry informative markers in clinical trials. The possible existence of geographic variation in accrual diversity is another important and relevant issue, but unfortunately these data were not uniformly available for all ACOSOG protocols. Discussions at ACOSOG meetings, however, indicated relatively greater success in recruiting HA patients from southwest sites in the United States (unpublished data).
In summary, our study of accrual patterns onto ACO-SOG clinical trials demonstrated that successful recruitment of minority racial/ethnic groups is indeed feasible, regardless of whether the protocol involves randomization and regardless of whether an investigational therapeutic drug is being offered. Trial eligibility limited to early-stage disease appears to be a barrier to clinical trial participation. Efforts to improve early detection of cancer in racial/ethnic minorities must be strengthened, and outreach to diverse patients for clinical trials evaluating locally advanced stages of disease should continue.
